AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7741289
Drug: Passive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive treatment 0.0 mA for 2 h (0 mA.min)
Trial: 27666126
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg for 5 days
Trial: 27666126
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg plus hydrochlorothiazide 25 mg for 5 days
Trial: 27666126
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg plus torasemide 5 mg for 5 days
Trial: 27666126
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg for 4 days
Trial: 27666126
Drug: Torasemide 5
RxNorm normalized name: Torasemide 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide 5 mg for 4 days
Trial: 23589316
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (Control group, N=31)
Trial: 23589316
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chemotherapy drugs and intraperitoneal perfusion of verapamil (Combined treatment group, N=41)
Trial: 23589316
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (N=41)
Trial: 8245520
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (1770 pfu/dose)
Trial: 8245520
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (400‐500 pfu/dose)
Trial: 8245520
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (80‐160 pfu/dose)
Trial: 29023192
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with Methylene Blue dye (0.01%) and laser therapy (660 nm, 30 mW, 8 sec, 6 J/cm2, beam area of 0.04 mm2), three times per week for 10 sessions
Trial: 26896305
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of 25‐30 min of aerobic exercise
Trial: 26896305
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of 50‐60 min of aerobic exercise
Trial: 26896305
Drug: Combined dose
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dose of 50‐60 min of aerobic and resistance exercise
Trial: 24886116
Drug: Behavioural activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural activation alone (treatment as usual)
Trial: 23450712
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for insomnia (CBTI) delivered in up to eight weekly telephone sessions (CBTI-Phone, n = 15)
Trial: 18490498
Drug: Subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin alfa
Trial: 19727208
Drug: Granulocyte colony
RxNorm normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Granulocyte colony stimulating factor (G-CSF)
Trial: 8648396
Drug: CSFs (GM-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSFs (GM-CSF or G-CSF) administered before or during induction therapy and following chemotherapy until neutrophil recovery
Trial: 3918430
Drug: Microbial beta-galactosidases
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbial beta-galactosidases added to 360 ml of cow milk containing 18 g of lactose
Trial: 24001105
Drug: Pumosetrag 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pumosetrag 0.2 mg
Trial: 24001105
Drug: Pumosetrag 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pumosetrag 0.5 mg
Trial: 24001105
Drug: Pumosetrag 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pumosetrag 0.8 mg
Trial: 22752418
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg kg(‐1 )day(‐1) ferrous sulfate for 6 months starting at 6 months of age
Trial: 17913720
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg every 12 h)
Trial: 10712318
Drug: Vancomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1 g every 12 h)
Trial: 1826046
Drug: Mesoglycan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesoglycan (100 mg/day) for six months
Trial: 1826046
Drug: Standard anti-platelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anti-platelet treatment for six months
Trial: 6372065
Drug: Trimipramine (Surmontil),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine (Surmontil), 50 mg at bedtime
Trial: 6372065
Drug: Cimetidine (Tagamet),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (Tagamet), 200 + 200 + 200 + 400 mg/day
Trial: 21054750
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ATC
Trial: 21054750
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ATC
Trial: 21054750
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg 3TC
Trial: 18506177
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA) administered at 2300 hours
Trial: 18506177
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA) administered at 1100 hours
Trial: 18506177
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (morning administration)
Trial: 12853354
Drug: CPT‐11 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 125 mg/m(2), FA 20 mg/m(2) followed by 5‐FU 500 mg/m(2) bolus, weekly for 4 weeks (arm A)
Trial: 12853354
Drug: CPT‐11 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 180 mg/m(2) day 1, FA 200 mg/m(2) over 2 h and 5‐FU 400 mg/m(2) bolus and 5‐FU 600 mg/m(2) 22‐h infusion on days 1 and 2, every 2 weeks (arm B)
Trial: 12853354
Drug: CPT‐11 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 350 mg/m(2) (days 1 and 43) alternating with FA 20 mg/m(2)/day followed by 5‐FU bolus 425 mg/m(2)/day during 5 days (days 22‐26) (arm C)
Trial: 8780093
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTA) injections
Trial: 8780093
Drug: Trihexyphenidyl tablets
RxNorm normalized name: trihexyphenidyl Oral Tablet
DrugBank: Trihexyphenidyl (DB00376)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trihexyphenidyl tablets plus placebo injection
Trial: 1633721
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 1000 mg twice daily
Trial: 1633721
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 500 mg twice daily
Trial: 1633721
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 10 mg/kg twice daily
Trial: 1633721
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 20 mg/kg twice daily
Trial: 1633721
Drug: Cefaclor 10
RxNorm normalized name: cefaclor 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 10 mg/kg 3-times daily
Trial: 1633721
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 500 mg twice daily (elderly subgroup)
Trial: 6360751
Drug: Indoprofen 400
RxNorm normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indoprofen 400 mg i.v.
Trial: 6360751
Drug: Pentazocine 30
RxNorm normalized name: pentazocine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 30 mg i.v.
Trial: 27545050
Drug: SIS augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIS augmentation (Restore Orthobiologic Implant; DePuy, Warsaw, IN, USA)
Trial: 27545050
Drug: SIS augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIS augmentation
Trial: 17440529
Drug: Kale meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kale meal (150 g)
Trial: 17440529
Drug: Kale meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kale meal with potassium oxalate drink (150 g kale + 1.26 g OA)
Trial: 17440529
Drug: Spinach meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinach meal (150 g)
Trial: 12025521
Drug: Sildenafil (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (initial dose 50 mg taken 1 h before sexual activity for the first 2 weeks, increased to 100 mg or decreased to 25 mg as needed)
Trial: 7486360
Drug: Prednisone, 20
RxNorm normalized name: PredniSONE, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 20 mg orally every 12 hours for 4 days
Trial: 25031133
Drug: Methylphenidate (0.2-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.2-1 mg/kg/d)
Trial: 25031133
Drug: Atomoxetine (0.5-1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (0.5-1.2 mg/kg/d)
Trial: 2393014
Drug: 400 mL
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mL regular coffee
Trial: 2393014
Drug: 165 mL
RxNorm normalized name: ALCOHOL 165 mL in 250 mL TOPICAL GEL [INSTANT HAND SANITIZER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 165 mL regular coffee
Trial: 2393014
Drug: 165 mL
RxNorm normalized name: ALCOHOL 165 mL in 250 mL TOPICAL GEL [INSTANT HAND SANITIZER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 165 mL decaffeinated coffee
Trial: 2393014
Drug: 165 mL
RxNorm normalized name: ALCOHOL 165 mL in 250 mL TOPICAL GEL [INSTANT HAND SANITIZER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 165 mL sodium chloride solution
Trial: 23696054
Drug: Tacrolimus plus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus plus steroids (ST)
Trial: 21310910
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL, given as three initial treatments with further retreatment as needed)
Trial: 17142654
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen 1 g iv every six hours plus oral placebo (group A)
Trial: 17142654
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen 400 mg po every six hours plus iv placebo (group I)
Trial: 14617059
Drug: Iontophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis with dexamethazone (3 ml)
Trial: 14617059
Drug: Iontophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis with saline solution (3 ml)
Trial: 8205268
Drug: Alpha-tocopherol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol (50 mg/day)
Trial: 8205268
Drug: Beta-carotene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (20 mg/day)
Trial: 8889344
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment identification by investigators
Trial: 8889344
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment identification by coordinators
Trial: 8889344
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment identification
Trial: 1889771
Drug: Hemodilution therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodilution therapy with hydroxyethyl-starch (HAES-steril) combined with pentoxifylline (Trental) for 6 months
Trial: 3963860
Drug: MY-1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MY-1 treatment (3 times a week from the 4th postoperative day for 3 weeks)
Trial: 27324515
Drug: 2% Chamaemelum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Chamaemelum nobile gel (0.5 mL/3 times a day)
Trial: 24338736
Drug: Repaglinide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (3 mg/day for 8 weeks)
Trial: 19657792
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone therapy (50 microg estradiol plus 170 microg norethisterone/day)
Trial: 16332385
Drug: Tiagabine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (4 mg, two oral doses)
Trial: 12556688
Drug: IL-2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 therapy (5 x 10(6) IU twice daily for 5 days: every 4 weeks for three cycles, then every 8 weeks for seven cycles)
Trial: 27012873
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g oral glucose
Trial: 10641582
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g oral glucose
Trial: 11238500
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g oral glucose
Trial: 8545223
Drug: High-dose surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose surfactant therapy (beractant, 150 mg (6 mL)/kg, up to four doses, instilled every 6 hours for 20 minutes)
Trial: 8545223
Drug: Air placebo
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air placebo (6 mL/kg)
Trial: 8545223
Drug: High-dose surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose surfactant therapy
Trial: 11910310
Drug: verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 240 mg/day
Trial: 6347788
Drug: verapamil 360
RxNorm normalized name: verapamil 360 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 360 mg/day
Trial: 29336385
Drug: Betamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (4 mg) with/without droperidol (0.625 mg)
Trial: 23143523
Drug: Oral antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotic medications
Trial: 20646185
Drug: Placebo (PLB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLB) gel (3-6 g/daily)
Trial: 8826572
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (divalproex sodium), starting dosage 250 mg bid, titrating to 1000 mg/d if necessary
Trial: 6373302
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg sublingual isosorbide dinitrate (ISDN)
Trial: 29343232
Drug: Dexmedetomidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2 μg∙kg‐1 (Group D2)
Trial: 29343232
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg∙kg‐1 (Group D1)
Trial: 28222678
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline (Group D0)
Trial: 29343232
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg∙kg‐1
Trial: 29343232
Drug: Dexmedetomidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2 μg∙kg‐1
Trial: 24823873
Drug: Exenatide treatment
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide treatment group (n=30)
Trial: 24823873
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy group (n=30)
Trial: 15798702
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enalapril with bisoprolol
Trial: 15798702
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enalapril with carvedilol
Trial: 15798702
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enalapril with irbesartan
Trial: 12065984
Drug: Posterior long
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior long fusion (surgical treatment)
Trial: 12065984
Drug: Nonoperated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperated group (conservative treatment)
Trial: 10452757
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP), 800 microg daily for 6 months
Trial: 2136866
Drug: Family intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Family intervention combined with drug treatment during hospitalization
Trial: 729629
Drug: Furosemide 50
RxNorm normalized name: furosemide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 50 mg administered orally
Trial: 729629
Drug: Furosemide 50
RxNorm normalized name: furosemide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 50 mg administered intravenously
Trial: 23706627
Drug: Minocycline 100mg
RxNorm normalized name: minocycline 100 MG
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 100mg orally, twice daily for 8 days
Trial: 21808963
Drug: Group MKH
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group MKH (midazolam 0.5 mg/kg and ketamine 6 mg/kg)
Trial: 21808963
Drug: Group MKL
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group MKL (midazolam 0.25 mg/kg and ketamine 3 mg/kg)
Trial: 21808963
Drug: Group M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group M (midazolam 0.5 mg/kg)
Trial: 19456855
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of amitriptyline
Trial: 15326251
Drug: High-dose betaINF-1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose betaINF-1a (60 microg IM/week)
Trial: 11241549
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg bicalutamide (Casodex)
Trial: 9250639
Drug: EMLA (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA (0.15 g/kg, maximum 5.0 g)
Trial: 9250639
Drug: TAC (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC (0.1 mL/kg, maximum 3.0 mL)
Trial: 2900918
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg ethyl loflazepate (CM 6912)
Trial: 2900918
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ethyl loflazepate (CM 6912)
Trial: 23406728
Drug: PEP02 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEP02 120 mg/m²
Trial: 23406728
Drug: irinotecan 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 300 mg/m²
Trial: 19925613
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (600 kcal/d)
Trial: 19925613
Drug: Control supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control supplement (200 kcal/d)
Trial: 16914336
Drug: FSC 500/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSC 500/50 microg Diskus, 1 inhalation twice daily + placebo Handihaler, 1 inhalation once daily
Trial: 16914336
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 microg Handihaler, 1 inhalation once daily + placebo Diskus, 1 inhalation twice daily